相关实验视频

Updated: May 16, 2025

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature

Published on: December 26, 2017

在糖尿病视网膜病变中通过非编码RNA对PI3K/AKT信号通路进行向治疗

Shuai Lu¹, Jian Cai²

¹Department of Pharmacy, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, Zhejiang, 311201, China.

Naunyn-Schmiedeberg's archives of pharmacology

|April 1, 2025

概括

酸-3-酶 (PI3K) 对于血糖控制至关重要. 本综述探讨了与PI3K/AKT通路相互作用的非编码RNA (ncRNA) 如何导致糖尿病视网膜病变 (DR),糖尿病并发症.

科学领域:

分子生物学分子生物学
内分泌学在内分泌学.
眼科医生眼科眼科

背景情况:

酸3-激酶 (PI3Ks) 对葡萄糖平衡至关重要;它们的功能障碍会导致糖尿病的特征高血糖症.
PI3K/AKT信号通路与各种非编码RNA (ncRNA) 相互作用,包括miRNA,lncRNA和circRNA.
在PI3K/AKT轴内的异常ncRNA调节与糖尿病病理生理学和糖尿病视网膜病变 (DR) 等并发症有关.

研究的目的:

审查ncRNAs在糖尿病视网膜病变 (DR) 中的致病作用.
阐明PI3K/AKT信号通路与DR中的特定miRNA,lncRNA和circRNA之间的复杂关系.
突出这些相互作用在底层的生物机制中的意义.

主要方法:

文献综述侧重于DR中ncRNAs的分子机制.
对研究PI3K/AKT信号与ncRNA之间的相互作用的分析.
综合当前关于ncRNA介导调节在DR中的临床相关性的数据.

主要成果:

有证据表明ncRNAs调节PI3K/AKT通路,影响与DR相关的细胞过程.
特定的miRNAs,lncRNAs和circRNAs已被确定为DR病变发生的关键参与者.
这些ncRNAs的失调有助于糖尿病患者的视网膜损伤.

结论:

针对特定的ncRNA提供了一个有前途的治疗策略,用于预防和治疗糖尿病视网膜病变.
了解ncRNA-PI3K/AKT轴相互作用对于开发新型DR治疗至关重要.
对DR中ncRNA功能的进一步研究是有必要的,以将发现转化为临床应用.

关键词:

糖尿病糖尿病糖尿病糖尿病视网膜病变 - 糖尿病视网膜病变这是一个MRNA和MRNA.没有编码的RNAs.信号传输信号传输

更多相关视频

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

Published on: January 12, 2024

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...